Navigation Links
Delcath Systems, Inc. Completes Phase III Study Enrollment
Date:10/21/2009

NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled. This clinical study is evaluating the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver.

With the achievement of complete enrollment, the company remains on-track for a FDA submission of its Delcath PHP System(TM) with melphalan in 2010. Trial enrollment will continue for the near-term to include additional patients that have begun the evaluation process and may be eligible to participate.

"We always expected to see the greatest enrollment activity in the second half of the study period as positive word about the Delcath PHP System spread and attracted new patients to the study," said Eamonn Hobbs, President and CEO of Delcath Systems. "We are delighted to have completed enrollment on-plan, and to continue the extremely positive momentum created over the last six months. We have achieved several key, strategic milestones, including the successful review of our Phase III safety data, orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma, and the additions of David McDonald as Chief Financial Officer and Dr. Krishna Kandarpa as Chief Medical Officer and EVP of Research and Development. We also executed on our plans to build our own manufacturing facility, which we will continue to develop as we focus for the remainder of the year on preparation for our FDA submission, commercialization and international licensing."

About the Phase
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
10. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Resources Group finds that the Asia Pacific ... , India , Japan ... Dental implant procedure volumes will grow as physicians are increasingly trained ... key findings from Decision Resources Group,s coverage of the ... Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 ... of the American Association of Tissue Banks (AATB), ... , Chief Executive Officer. Accreditation follows ... by a specially trained AATB inspector.  It establishes ... performance within the facility meets or exceeds the ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2
... Lilly and Company (NYSE: LLY ) today ... Radiopharmaceuticals, Inc., a privately held company developing novel molecular ... chronic human diseases. The transaction, first announced on November ... and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All ...
... year, the Food and Drug Administration (FDA) approves many ... and help consumers save money. To read ... to http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm236544.htm . Sign up for ... https://service.govdelivery.com/service/subscribe.html?code=USFDA_9 . View the ...
Cached Medicine Technology:Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir 2
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Children conceived either ... the birth of a sibling could be at increased risk ... study,s lead author and an outside expert agree that the ... in autism. "Most importantly, it is important that parents ... even when pregnancies are close together or far apart," said ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... Next to lung cancer, breast cancer is the leading ... American Cancer Society. That,s why so many medical professionals ... are imperfect at best: only a minority of suspicious ... results in lots of needless worry for women and ... of additional tests, including ultrasounds and biopsies. , ...
(Date:9/30/2014)... slow the spiraling costs of drugs paid for by ... no meaningful impact on cancer chemotherapy drug costs, say ... Clinical Oncology published online today. , "We looked ... lung cancers, and did not find a substantial change ... of the recent Medicare law in 2005," says the ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s leader ... specialty practice through a unique partnership with an established ... within the company’s Shrewsbury location and will be staffed ... American Heart Center, P.C., a highly regarded practice located ... Medicine Alliance patients top notch cardiovascular care without leaving ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... FAIRFAX, Va., July 27 A new proposal from the Centers ... therapy treatments would cause many cancer centers to close, stop accepting ... patients, according to a survey conducted by ASTRO, the American Society ... technology has allowed radiation oncologists to improve cancer cure rates while ...
... , St. Jude scientists identify new ... the need for more detailed look at the complete AML genome ... The most comprehensive analysis yet of the genome of childhood acute ... blueprint, suggesting the cancer arises from just a handful of missteps, ...
... serious complications drop with intensive therapy, study shows , ... blood sugar levels and taking medications that lower blood ... significantly reduce their risk of developing the most serious ... In a study appearing in the July 27 issue ...
... , , SWIFTWATER, ... Group (EURONEXT: SAN and NYSE: SNY ), announced today ... of Fluzone((R)), Influenza Virus Vaccine. Fluzone vaccine is indicated for active ... disease caused by influenza virus subtypes A and type B contained ...
... , DENVER, July 27 ... come together to offer Chamber members a health plan solution that ... traditional and alternative medical care. Whether members choose to treat a ... regimens, the Chamber Plan,s BlueFreedom accommodates their healing preferences. Most plan ...
... , MONDAY, July 27 (HealthDay News) -- Ozone levels ... on lung function in healthy people, say U.S. researchers. , ... of up to 75 parts per billion over an eight-hour ... to mean ozone concentrations as low as 70 parts per ...
Cached Medicine News:Health News:Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey 2Health News:Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey 3Health News:Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey 4Health News:Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease 2Health News:Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease 3Health News:Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease 4Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 2Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 3Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 4Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 5Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 6Health News:Anthem Blue Cross and Blue Shield Introduces a Health Insurance Solution With a Special 'Boulder Flair' to Chamber Members 2Health News:'Safe' Ozone Levels May Not Be for Some 2
... first 192 channel simultaneous sampling EEG with ... routine EEG exam rooms as well as ... Optional analysis software for automatic spike ... sleep analysis. Quality Data Acquisition ,The ...
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
... The VISULAS 690s is the ... the instrument of choice for ... clinical trials, Carl Zeiss has ... in laser manufacturing to create ...
The SL 115 Classic Slit Lamp offers you high optical performance and convenient operation. It is not only the ideal instrument for all routine examinations and contact lens fitting, but is also excel...
Medicine Products: